Cambridge Investment Research Advisors’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio MBVX Stock Details MBVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-582,855	Closed	-$29K	–	2454
2019 Q2	$29K	Buy	+582,855	New	+$29K	﹤0.01%	2172
2018 Q3	–	Sell	-1,030,310	Closed	-$876K	–	2352
2018 Q2	$876K	Buy	1,030,310 +49,967	+5%	+$63.3K	0.01%	1054
2018 Q1	$1.48M	Sell	980,343 -39,225	-4%	-$84.8K	0.02%	742
2017 Q4	$2.14M	Buy	1,019,568 +187,834	+23%	+$415K	0.03%	564
2017 Q3	$1.62M	Buy	+831,734	New	+$1.82M	0.02%	608

Cambridge Investment Research Advisors's MBVX Position: Q3 2019 in Review

Cambridge Investment Research Advisors sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q3 2019, closing a stake of 582,855 shares — an estimated $29K sold.

Cambridge Investment Research Advisors first reported a position in MBVX in Q3 2017 and held it in 5 quarters. The position peaked at $2.14M in Q4 2017. 0 funds tracked by Wall St. Rank hold MBVX as of Q3 2019.

Cambridge Investment Research Advisors reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q3 2019 after selling out during the quarter.
Cambridge Investment Research Advisors sold 582,855 MABVAX THERAPEUTICS HLDGS INC shares in Q3 2019, an estimated $29K.
Cambridge Investment Research Advisors first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q3 2017 and held it in 5 quarters.
Cambridge Investment Research Advisors's MABVAX THERAPEUTICS HLDGS INC position peaked at $2.14M in Q4 2017.
0 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q3 2019.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2019, filed 28 Oct 2019.